These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 11042238)

  • 1. Management and dosing of warfarin therapy.
    Gage BF; Fihn SD; White RH
    Am J Med; 2000 Oct; 109(6):481-8. PubMed ID: 11042238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Ansell J; Hirsh J; Poller L; Bussey H; Jacobson A; Hylek E
    Chest; 2004 Sep; 126(3 Suppl):204S-233S. PubMed ID: 15383473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update of consensus guidelines for warfarin reversal.
    Tran HA; Chunilal SD; Harper PL; Tran H; Wood EM; Gallus AS;
    Med J Aust; 2013 Mar; 198(4):198-9. PubMed ID: 23451962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin k with genomic considerations: a pilot study.
    Bussey HI; Bussey M; Bussey-Smith KL; Frei CR
    Pharmacotherapy; 2013 Nov; 33(11):1136-46. PubMed ID: 24038412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosing options for decreasing the time to achieve therapeutic anticoagulation when reinitiating warfarin: a case series.
    Schultz KT; Bungard TJ
    Pharmacotherapy; 2011 Aug; 31(8):793-805. PubMed ID: 21923606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation.
    Hylek EM; Chang YC; Skates SJ; Hughes RA; Singer DE
    Arch Intern Med; 2000 Jun; 160(11):1612-7. PubMed ID: 10847254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
    Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
    Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin K dosing to reverse warfarin based on INR, route of administration, and home warfarin dose in the acute/critical care setting.
    Tsu LV; Dienes JE; Dager WE
    Ann Pharmacother; 2012 Dec; 46(12):1617-26. PubMed ID: 23249867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended International Normalized Ratio testing intervals for warfarin-treated patients.
    Barnes GD; Kong X; Cole D; Haymart B; Kline-Rogers E; Almany S; Dahu M; Ekola M; Kaatz S; Kozlowski J; Froehlich JB
    J Thromb Haemost; 2018 Jul; 16(7):1307-1312. PubMed ID: 29763979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of rivaroxaban to the international normalized ratio when switching to warfarin for anticoagulation as determined by simulation studies.
    Siegmund HU; Burghaus R; Kubitza D; Coboeken K
    Br J Clin Pharmacol; 2015 Jun; 79(6):959-66. PubMed ID: 25510952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin.
    Hylek EM; Regan S; Go AS; Hughes RA; Singer DE; Skates SJ
    Ann Intern Med; 2001 Sep; 135(6):393-400. PubMed ID: 11560452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis.
    Baker RI; Coughlin PB; Gallus AS; Harper PL; Salem HH; Wood EM;
    Med J Aust; 2004 Nov; 181(9):492-7. PubMed ID: 15516194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new regimen for starting warfarin therapy in out-patients.
    Oates A; Jackson PR; Austin CA; Channer KS
    Br J Clin Pharmacol; 1998 Aug; 46(2):157-61. PubMed ID: 9723825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approaches to optimal dosing of vitamin K antagonists.
    Witt DM
    Semin Thromb Hemost; 2012 Oct; 38(7):667-72. PubMed ID: 22893509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dietary vitamin K variability affects International Normalized Ratio (INR) coagulation indices.
    Couris R; Tataronis G; McCloskey W; Oertel L; Dallal G; Dwyer J; Blumberg JB
    Int J Vitam Nutr Res; 2006 Mar; 76(2):65-74. PubMed ID: 16941417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Warfarin dose reduction vs watchful waiting for mild elevations in the international normalized ratio.
    Banet GA; Waterman AD; Milligan PE; Gatchel SK; Gage BF
    Chest; 2003 Feb; 123(2):499-503. PubMed ID: 12576372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized controlled trial of empiric warfarin dose reduction with the initiation of doxycycline therapy.
    Dowd MB; Kippes KA; Witt DM; Delate T; Martinez K
    Thromb Res; 2012 Aug; 130(2):152-6. PubMed ID: 22221937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of warfarin dosing in the intensive care unit following the Fontan procedure.
    Thomas CA; Taylor K; Schamberger MS; Rotta AT
    Congenit Heart Dis; 2014; 9(4):361-5. PubMed ID: 25247218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematology consult: high-sensitivity warfarin genotype.
    Schwer C; Lamana S; Dasanu CA
    Conn Med; 2013; 77(10):581-5. PubMed ID: 24367840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective evaluation of vitamin K1 therapy to reverse the anticoagulant effect of warfarin.
    Fan J; Armitstead JA; Adams AG; Davis GA
    Pharmacotherapy; 2003 Oct; 23(10):1245-50. PubMed ID: 14594342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.